PFC Capital Group Inc. Has $1.53 Million Stock Holdings in Amgen Inc. (NASDAQ:AMGN)

PFC Capital Group Inc. decreased its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 14.3% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 5,855 shares of the medical research company’s stock after selling 980 shares during the quarter. Amgen comprises about 0.7% of PFC Capital Group Inc.’s portfolio, making the stock its 29th biggest holding. PFC Capital Group Inc.’s holdings in Amgen were worth $1,526,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Centricity Wealth Management LLC acquired a new stake in Amgen in the 4th quarter valued at about $25,000. Legacy Investment Solutions LLC bought a new stake in Amgen in the third quarter valued at approximately $29,000. Synergy Investment Management LLC acquired a new stake in shares of Amgen in the fourth quarter valued at approximately $34,000. Atala Financial Inc acquired a new stake in shares of Amgen in the fourth quarter valued at approximately $34,000. Finally, Heck Capital Advisors LLC bought a new position in shares of Amgen during the 4th quarter worth approximately $36,000. Institutional investors own 76.50% of the company’s stock.

Amgen Trading Up 1.5 %

Shares of NASDAQ AMGN opened at $311.55 on Tuesday. The company has a market cap of $167.37 billion, a PE ratio of 41.26, a P/E/G ratio of 2.63 and a beta of 0.53. Amgen Inc. has a 52-week low of $253.30 and a 52-week high of $346.85. The company has a debt-to-equity ratio of 9.62, a quick ratio of 0.95 and a current ratio of 1.26. The firm’s 50 day moving average price is $301.87 and its 200-day moving average price is $297.81.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Tuesday, February 4th. The medical research company reported $5.31 EPS for the quarter, beating analysts’ consensus estimates of $5.04 by $0.27. Amgen had a return on equity of 176.32% and a net margin of 12.24%. On average, equities research analysts expect that Amgen Inc. will post 20.62 EPS for the current fiscal year.

Amgen Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, June 6th. Stockholders of record on Friday, May 16th will be given a dividend of $2.38 per share. This represents a $9.52 annualized dividend and a dividend yield of 3.06%. The ex-dividend date of this dividend is Friday, May 16th. Amgen’s dividend payout ratio is currently 126.09%.

Insider Transactions at Amgen

In other Amgen news, EVP David M. Reese sold 25,225 shares of the company’s stock in a transaction on Friday, February 21st. The stock was sold at an average price of $304.44, for a total value of $7,679,499.00. Following the completion of the sale, the executive vice president now directly owns 36,922 shares in the company, valued at approximately $11,240,533.68. This represents a 40.59 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Jonathan P. Graham sold 25,045 shares of Amgen stock in a transaction that occurred on Friday, February 7th. The shares were sold at an average price of $293.12, for a total transaction of $7,341,190.40. Following the transaction, the executive vice president now directly owns 28,987 shares in the company, valued at approximately $8,496,669.44. The trade was a 46.35 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 69,341 shares of company stock worth $20,644,335. 0.69% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on the stock. StockNews.com upgraded shares of Amgen from a “buy” rating to a “strong-buy” rating in a report on Saturday. Johnson Rice set a $294.00 price target on shares of Amgen in a research note on Wednesday, March 5th. UBS Group restated a “hold” rating on shares of Amgen in a research report on Wednesday, February 12th. Piper Sandler Companies reiterated an “overweight” rating and set a $310.00 target price on shares of Amgen in a research note on Thursday, January 2nd. Finally, Truist Financial reduced their price target on Amgen from $333.00 to $298.00 and set a “hold” rating for the company in a research note on Wednesday, January 8th. Two research analysts have rated the stock with a sell rating, nine have given a hold rating, eleven have given a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, Amgen presently has an average rating of “Moderate Buy” and an average target price of $314.04.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.